{"nctId":"NCT02107898","briefTitle":"Efficacy and Safety Evaluation of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia or High Cardiovascular Risk Patients With Hypercholesterolemia on Lipid Modifying Therapy (ODYSSEY JAPAN)","startDateStruct":{"date":"2014-03"},"conditions":["Hypercholesterolemia"],"count":216,"armGroups":[{"label":"Placebo Q2W","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo (for alirocumab)","Drug: Lipid-Modifying Therapy (LMT)"]},{"label":"Alirocumab 75 mg/Up to 150 mg Q2W","type":"EXPERIMENTAL","interventionNames":["Drug: Alirocumab","Drug: Lipid-Modifying Therapy (LMT)"]}],"interventions":[{"name":"Placebo (for alirocumab)","otherNames":[]},{"name":"Alirocumab","otherNames":["SAR236553","REGN727","Praluent"]},{"name":"Lipid-Modifying Therapy (LMT)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\nParticipants with heterozygous familial hypercholesterolemia or non-familial hypercholesterolemia who were not adequately controlled with a stable daily dose of statin with or without other lipid modifying therapy, at stable dose prior to the screening visit (Week -3).\n\nExclusion criteria:\n\n1. LDL-C \\<100 mg/dL (\\<2.59 mmol/L) at the screening visit in participants with heterozygous familial hypercholesterolemia or in participants with non-familial hypercholesterolemia who had a history of documented coronary heart disease as described in Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012.\n2. LDL-C \\<120 mg/dL (\\<3.10 mmol/L) at the screening visit in participants with non-familial hypercholesterolemia who had a history of documented diseases or other risk factors as categorized in primary prevention category III as described in JAS Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012.\n3. Not on a stable daily dose of lipid modifying therapy (including statin) within 4 weeks prior to the screening visit or between screening and randomization visits.\n4. Age \\<20 years at the screening visit.\n\nThe above information is not intended to contain all considerations relevant to a participants' potential participation in a clinical trial.","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT Analysis)","description":"Adjusted least-squares (LS) means and standard errors at Week 24 were obtained from a mixed-effect model with repeated measures (MMRM) to account for missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were used in the model (ITT analysis).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":"1.8"},{"groupId":"OG001","value":"-62.5","spread":"1.3"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis","description":"Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection) (on-treatment analysis).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":"1.7"},{"groupId":"OG001","value":"-63.7","spread":"1.2"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis","description":"Adjusted LS means and standard errors at Week 12 from MMRM model including available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.7","spread":"1.6"},{"groupId":"OG001","value":"-64.2","spread":"1.1"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Calculated LDL-C at Week 12 - On-treatment Analysis","description":"Adjusted LS means and standard errors at Week 12 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.8","spread":"1.5"},{"groupId":"OG001","value":"-64.8","spread":"1.1"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 - ITT Analysis","description":"Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.6","spread":"1.7"},{"groupId":"OG001","value":"-55.0","spread":"1.2"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Apo B at Week 24 - On-Treatment Analysis","description":"Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.1","spread":"1.7"},{"groupId":"OG001","value":"-55.9","spread":"1.2"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis","description":"Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.6","spread":"1.6"},{"groupId":"OG001","value":"-54.9","spread":"1.2"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Non-HDL-C at Week 24 - On-Treatment Analysis","description":"Adjusted LS means and standard errors at Week 24 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.6","spread":"1.6"},{"groupId":"OG001","value":"-56.0","spread":"1.1"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis","description":"Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":"1.3"},{"groupId":"OG001","value":"-39.5","spread":"0.9"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Apo B at Week 12 - ITT Analysis","description":"Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.3","spread":"1.5"},{"groupId":"OG001","value":"-54.6","spread":"1.1"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis","description":"Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.7","spread":"1.4"},{"groupId":"OG001","value":"-56.3","spread":"1.0"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Total-C at Week 12 - ITT Analysis","description":"Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.1","spread":"1.1"},{"groupId":"OG001","value":"-41.1","spread":"0.8"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Reaching Calculated LDL-C Goal at Week 24 - ITT Analysis","description":"Calculated LDL-C goal was defined as:\n\n* \\<100 mg/dL (2.59 mmol/L) for heFH or non-FH participants who had a history of documented congestive heart disease (CHD), or\n* \\<120 mg/dL (3.10 mmol/L) for non-FH participants who had a history of documented diseases (ischemic stroke, peripheral artery disease, chronic kidney disease or diabetes) or other risk factors as defined in JAS Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012.\n\nAdjusted percentages at Week 24 were obtained from multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were included in imputation model.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.2","spread":null},{"groupId":"OG001","value":"96.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Reaching Calculated LDL-C Goal at Week 24 - On-Treatment Analysis","description":"Adjusted percentages at Week 24 were from multiple imputation approach model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.6","spread":null},{"groupId":"OG001","value":"97.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Lipoprotein (a) at Week 24 - ITT Analysis","description":"Adjusted means and standard errors at Week 24 from a multiple imputation approach followed by robust regression model for handling of missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment were included in the imputation model.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":"2.5"},{"groupId":"OG001","value":"-39.5","spread":"1.8"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis","description":"Adjusted means and standard errors at Week 24 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7","spread":"3.7"},{"groupId":"OG001","value":"-15.3","spread":"2.6"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis","description":"Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":"1.5"},{"groupId":"OG001","value":"7.9","spread":"1.1"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Apo A1 at Week 24 - ITT Analysis","description":"Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.6","spread":"1.6"},{"groupId":"OG001","value":"1.4","spread":"1.1"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Lipoprotein (a) at Week 12 - ITT Analysis","description":"Adjusted means and standard errors at Week 12 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"2.4"},{"groupId":"OG001","value":"-41.9","spread":"1.7"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis","description":"Adjusted means and standard errors at Week 12 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":"3.7"},{"groupId":"OG001","value":"-13.1","spread":"2.6"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis","description":"Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.8","spread":"1.2"},{"groupId":"OG001","value":"4.7","spread":"0.8"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Apo A1 at Week 12 - ITT Analysis","description":"Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.8","spread":"1.1"},{"groupId":"OG001","value":"1.5","spread":"0.8"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percent Change From Baseline in Calculated LDL-C at Week 52 - ITT Analysis","description":"Adjusted LS means and standard errors at Week 52 from MMRM model including available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.6","spread":"1.9"},{"groupId":"OG001","value":"-62.5","spread":"1.4"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percent Change From Baseline in Calculated LDL-C at Week 52 - On-Treatment Analysis","description":"Adjusted LS means and standard errors at Week 52 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 52 (i.e. up to 21 days after last injection).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.4","spread":"1.7"},{"groupId":"OG001","value":"-64.6","spread":"1.2"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":9,"n":72},"commonTop":["Nasopharyngitis","Back pain","Injection site reaction","Diabetes mellitus","Fall"]}}}